Home
Mail
News
Sport
Finance
Celebrity
Style
Weather
Mobile
Messenger
Movies
More
Yahoo
Mail
News
Market Data
Crypto
Bank of England
Money Matters
Property
Top Stocks
Work & Management
Industry News
Brexit
My Portfolio
My Screeners
Watchlists
Videos
UK markets open in 2 hours 12 minutes
NIKKEI 225
38,236.07
-37.98
(-0.10%)
HANG SENG
18,413.79
+206.66
(+1.14%)
CRUDE OIL
79.20
+0.25
(+0.32%)
GOLD FUTURES
2,314.80
+5.20
(+0.23%)
DOW
38,225.66
+322.37
(+0.85%)
Bitcoin GBP
47,466.26
+1,700.86
(+3.72%)
Money
Best UK mortgage deals of the week
The cheapest home loans available now
Cyclacel Pharmaceuticals, Inc. (CYCC)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4900
-0.1600
(-6.04%)
At close: 04:00PM EDT
2.2800
-0.21
(-8.43%)
After hours:
07:58PM EDT
Summary
Chart
Conversations
Statistics
Historical data
Profile
Financials
Analysis
Options
Holders
Sustainability
Show
:
Income statement
Balance sheet
Cash flow
Annual
Quarterly
Income statement
All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
420
420
0
0
0
Operating expenses
Research development
19,155
19,155
20,274
14,928
4,759
Selling general and administrative
6,718
6,718
7,382
7,461
5,877
Total operating expenses
25,873
25,873
27,656
22,389
10,636
Operating income or loss
-25,453
-25,453
-27,656
-22,389
-10,636
Total other income/expenses net
-364
-364
1,531
188
913
Income before tax
-25,551
-25,551
-25,915
-22,185
-9,681
Income tax expense
-2,996
-2,996
-4,717
-3,728
-1,236
Income from continuing operations
-22,555
-22,555
-21,198
-18,457
-8,445
Net income
-22,555
-22,555
-21,198
-18,457
-8,445
Net income available to common shareholders
-22,756
-22,756
-21,399
-18,658
-12,421
Basic EPS
-29.85
-26.75
-28.70
-32.10
-51.30
Diluted EPS
-29.85
-26.75
-28.70
-32.10
-51.30
Basic average shares
838.137
850.815
657.62
595.078
242.225
Diluted average shares
838.137
850.815
657.62
595.078
242.225
Data disclaimer
Help
Suggestions
Terms
and
Privacy Policy
Privacy dashboard
About our ads
© 2024 Yahoo. All rights reserved.